Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Writer
California, {6D506EDE-F0E4-4964-93FF-D8A3DA23BDA0}
+26 year(s) experience
Emily has over 20 years’ experience as a writer/editor in medical journalism, including magazines for specialist clinicians, pharma trade press, government health publications and business newswires. Since 2008, she has been a senior writer on staff with Pink Sheet and Scrip. In her free time, she is a professional vocalist.
Scrip
By Emily Hayes 21 Feb 2019
Analyst speculates that risk of pulmonary embolism for a higher unapproved of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.
Topic Arthritis
Scrip
By Emily Hayes 26 Sep 2018
Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.
Topic Cancer
Scrip
By Emily Hayes 26 Sep 2018
Roche's combination of Tecentriq with chemotherapy is ahead of rivals in first-line SCLC and has been filed with the US FDA.
Topic Cancer
Scrip
By Emily Hayes 22 Aug 2018
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Scrip
By Emily Hayes 22 Aug 2018
With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.
Topic Cancer
Scrip
By Emily Hayes 22 Aug 2018
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Topic Obesity Clinical trials
Pink Sheet
By Emily Hayes 22 Aug 2018
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.
Scrip
By Emily Hayes 21 Jun 2018
Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.
Topic Diabetes
Scrip
By Emily Hayes 18 May 2018
Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.
Topic Cancer
Scrip
By Emily Hayes 16 May 2018
There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.
Topic Cancer
Scrip
By Emily Hayes 25 Dec 2017
Merck's KEYNOTE-061 gastric cancer study is the latest example of a checkpoint inhibitor failing.
Topic Cancer
Scrip
By Emily Hayes 11 Dec 2017
Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies.
Topic Cancer
Scrip
By Emily Hayes 29 Nov 2017
Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications.
Topic Clinical trials
Pink Sheet
By Emily Hayes 18 Sep 2017
An 'imperfect biomarker' – that's how a New England Journal of Medicine editorial describes the eosinophil count used in METREX and METREO studies.
Topic Clinical trials
Scrip
By Emily Hayes 21 Aug 2017
FDA approval of an antidote for Factor Xa novel anticoagulants would further drive the already strong uptake of J&J/Bayer's Xarelto and Bristol/Pfizer's Eliquis, analysts say.
Scrip
03 Apr 2019
Scrip
01 Apr 2019
Scrip
26 Mar 2019
Scrip
22 Mar 2019
Scrip
20 Mar 2019
Scrip
15 Mar 2019
Scrip
13 Mar 2019
Scrip
08 Mar 2019
Scrip
06 Mar 2019
Scrip
05 Mar 2019
Scrip
20 Feb 2019
Scrip
19 Feb 2019
Scrip
19 Feb 2019
Scrip
14 Feb 2019
Scrip
08 Feb 2019
